There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit ...

Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...

We take a closer look at Gilead's pipeline strategy and dealmaking activity in 2026 as the company attempts to broaden its ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

AACR 2026 saw thousands gathered in San Diego, California, where major progress in cancer research was revealed.

Single-cell analysis is reshaping drug discovery, but interpretation remains slow. AI single cell approaches may close the ...

Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers.

Discover some of the new atopic dermatitis treatments in clinical development that could overcome existing challenges in the ...

For this year’s ‘biotechs to watch’ selection, each Labiotech journalist picked five companies they believe will be worth following in 2026. Some earned their spot after clear momentum in 2025, while ...